GcMAF

GcMAF purportedly activates macrophages (phagocytosis/cAMP ↑) and curbs angiogenesis (CAM/tube ↓), with theoretical tumor apoptosis/immunity boost—but retracted/controversial evidence; unapproved 100–500 ng SC weekly; high risk, research-only.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐ Controversial — Limited preclinical data; no strong clinical evidence, with ongoing debates.Gc protein-derived macrophage-activating factorGcMAFVitamin D-binding protein-derived macrophage activating factor

Forms: Subcutaneous injections (unapproved/research, 100 ng/vial)

Educational only, not medical advice. OncoForge makes no claim that GcMAF treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Proposed macrophage activator with anti-angiogenic signals in early studies, but evidence is controversial and lacks robust clinical validation.

Evidence at a glance

Tier 1 · labProstateBreastGeneral (controversial)

Controversial/limited preclinical; retracted claims; no validated clinical data; ongoing pilot scrutiny.

How it may work

GcMAF (Gc protein-derived macrophage-activating factor) is proposed to activate macrophages by converting vitamin D-binding protein (Gc protein) into a form that stimulates macrophage phagocytosis and cytotoxicity against cancer cells. It may inhibit angiogenesis by suppressing endothelial cell proliferation and induce apoptosis in tumor cells. However, evidence is controversial, with limited preclinical data showing effects on cAMP formation and immune modulation, but no robust clinical validation due to regulatory issues and retracted studies.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Macrophage Activation↑Stimulates phagocytosis/cytotoxicity via cAMP; TNF-α/IL-12 ↑
Angiogenesis↓Suppresses endothelial proliferation/tube formation
Apoptosis↑In tumor cells; immune-mediated
Immune Modulation↑Enhances overall anti-tumor immunity (theoretical)

MacrophageAngio

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Vitamin D: Theoretical Gc conversion aid.

Overlapping mechanisms

Macrophage ↑ / Angio ↓: Avoid with other macrophage/anti-angio agents; unproven base risks futility/tox without data.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Injection ReactionsImmunogenicity RiskRegulatory RiskPregnancy Avoid

Potential interactions

Immunosuppressants (e.g., steroids)AvoidSevereTheoreticalMay blunt macrophage activation.
Vitamin DConsiderBeneficialTheoreticalTheoretical complement for Gc protein conversion.

Timing

Weekly injections: Subcutaneous; rotate sites.
Monitor nagalase: Every 4–6 weeks to assess response.

References

Research

No published studies for GcMAF yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of GcMAF depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 100–500 ng (sc) Early studies: 100 ng weekly subcutaneous injections for 4–6 months. Some protocols: 100–500 ng/week, titrated based on nagalase levels. No established HED due to lack of trials; experimental only., Unapproved; sourced from unregulated labs. Half-life ~15 days; monitor nagalase as surrogate. Strictly research/clinical trial settings; self-administration discouraged..

Trials studying GcMAF

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar